Oxford Cancer Analytics

Oxford Cancer Analytics is a private, pre-revenue diagnostics company founded in 2016 and based in Oxford, UK. It is developing a proprietary platform that combines high-throughput proteomic analysis of blood samples with advanced machine learning to generate diagnostic and prognostic insights for lung diseases, starting with COPD. The company's mission is to transform fragmented and slow diagnostic pathways by providing scalable, biologically grounded tools that enable earlier intervention and more consistent clinical decision-making. Led by a team with expertise in diagnostics, AI, and clinical medicine, OXcan represents a convergence of proteomics and computational biology aimed at a significant global health burden.

DEcancer platform: A proprietary diagnostic platform combining high-throughput proteomic analysis of the circulating proteome from blood samples with advanced machine learning and AI algorithms to identify disease-specific signatures for clinical decision support.

OXcan operates in the competitive AI-driven diagnostics space. In lung cancer, it faces well-funded players like Grail and Guardant Health. In COPD, the competitive field is less defined but requires displacing established, if imperfect, diagnostic standards. Differentiation will hinge on the unique predictive power of its proteomic signatures and demonstrated clinical utility.